TRIP6 and hepatocellular carcinoma: Otherwise, Zhao et al. [35] observed that FOXO3 transactivity is impaired in HCC due to FOXO3 downregulation, which could be linked with the enhancement of cell proliferation promoted by thyroid hormone receptor-interacting protein 6 (TRIP6).